The Babraham Institute aims to maximise the impact of its scientific discoveries; where appropriate this is achieved through commercialisation of its intellectual property rights. This primarily involves licensing new discoveries and technologies to pharma and biotech companies, but in some cases commercialisation is achieved through spinning out new companies (for example Crescendo Biologics Ltd).
Current opportunities for licensing the Babraham Institute’s intellectual property include:
PatentsEnhancing the potency of stem cells Download flier
International patent applications filed in USA, Europe, Japan, Australia, Canada, China. (priority date 17th December 2012) Worldwide
VDJ-Seq Download flier
International patent applications filed in Europe, USA and Japan (priority date 2nd March 2012) Non-exclusive, worldwide
Capture Hi-C: Deciphering the 3D folding of the genome
Please contact us for further details.
Priority patent application filed 5th September 2013. Worldwide
ReagentsAll available via Ximbio
Monoclonal antibody against 5-hydroxymethylcytosine
Ficz et al (2010) Nature 473, 398-402
Conditional p110δ knockout mice
Rolf et al (2010) J Immunol 185(7), 4042-52
Germline p110δ knockout mice
Clayton et al (2002) J Exp Med 196(6), 753-63
Tau P301L knockin mice
Gilley et al (2012) Neurobiol Aging 33 621.e1-621.e15
Nmnat2-Venus transgenic mice
Milde et al (2013) Sci Rep 3, 2567
Monoclonal Antibody against 5-hmC
The monoclonal antibody developed has proved of value for assays of this epigenetic mark and has now been licensed non-exclusively to several companies.
Contact UsPlease contact us if you are interested in licensing Babraham Institute discoveries.
Dr Katy Evans-Roberts, Commercialisation Manager
+44 (0)1223 496208